Patrick Daly
Articles by Patrick Daly
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
The MAA for RP-L102, an investigational gene therapy for Fanconi anemia, has been approved by the EMA.
Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS.
The European Commission approved an expanded indication for luspatercept as first-line therapy for anemia in lower-risk MDS.
A standardized, local TCD supported by central quality review was implemented effectively in resource-constrained settings.
The US FDA has approved danicopan as an add-on therapy in patients with PNH and EVH on standard-of-care C5 inhibitor therapy.
The US FDA has approved vadadustat to treat anemia due to CKD in adults who have been on dialysis for at least three months.
The US FDA has approved an expanded indication for IXINITY to control bleeding in all patients with hemophilia B.
ASPHO President Caroline Hastings, MD, offers highlights from the 2024 ASPHO conference in Seattle, WA.
The US FDA ODAC voted that the benefits of imetelstat for managing anemia in lower-risk MDS outweigh the risks.
Efficacy appeared to be similar among DOACs for managing cancer-related VTE, though apixaban may have more favorable safety.
VRd was associated with lower rates of venous thromboembolism versus KRd in patients with newly-diagnosed multiple myeloma.
Iptacopan monotherapy improved hematologic and clinical outcomes of persistent anemia in patients with PNH.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.